Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
Active, not recruiting · NCT07033481 · Registry updated 2026-07-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia | Frontotemporal Lobar Degeneration, Neurobehavioral Manifestations, Neurologic Manifestations, Nutritional and Metabolic Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, aphasia, brain disorder, central nervous system disorder, cognitive disorder, communication disorder, dementia, frontotemporal dementia, language disorder, metabolic disease, nervous system disorder, neurodegenerative disease, primary progressive aphasia, proteostasis deficiencies, psychiatric disorder, speech disorder | Active, not recruiting | Phase 2 | 2026-07-06 | NCT07033481 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| CervoMed, Inc. | 2 |
| EIP Pharma Inc | 2 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Clinical Ageing Research Unit, Campus for Ageing and Vitality, Biomedical Research Building | Newcastle upon Tyne | United Kingdom | 1 |
| Columbia University | New York | United States | 154 |
| Hospital of the University of Pennsylvania | Philadelphia | United States | 142 |
| Mayo Clinic | Rochester | United States | 664 |
| Northwestern Memorial Hospital | Chicago | United States | 129 |
| The Ohio State University | Columbus | United States | 13 |
| Windsor Research Unit, Fulbourn Hospital | Cambridge | United Kingdom | 1 |